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Abstract
Background: Soft-shelled turtle iridovirus (STIV) causes severe systemic disease in farmed soft-shelled turtles
(Trionyx sinensis). More efficient methods of controlling and detecting STIV infections are urgently needed.
Methods: In this study, we generated eight single-stranded DNA (ssDNA) aptamers against STIV using systematic
evolution of ligands by exponential enrichment (SELEX).
Results: The aptamers formed representative stem-loop secondary structures. Electrophoretic mobility shift assays and
fluorescent localization showed that the selected aptamers had high binding affinity for STIV. Aptamer QA-36 had the
highest calculated binding affinity (Kd) of 53.8 nM. Flow cytometry and fluorescence microscopy of cell-aptamer
interactions demonstrated that QA-12 was able to recognize both STIV-infected cells and tissues with a high level of
specificity. Moreover, the selected aptamers inhibited STIV infection in vitro and in vivo, with aptamer QA-36
demonstrating the greatest protective effect against STIV and inhibiting STIV infection in a dose-dependent manner.
Discussion: We generated DNA aptamers that bound STIV with a high level of specificity, providing an alternative
means for investigating STIV pathogenesis, drug development, and medical therapies for STIV infection.
Conclusions: These DNA aptamers may thus be suitable antiviral candidates for the control of STIV infections.
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Background
The Chinese soft-shelled turtle (Trionyx sinensis) has
high nutritional and economic values and is cultured
commercially in China and other Asian countries, such
as Japan, Vietnam and Korea [1]. Moreover, the turtle’s
unique body plan makes it a useful model organism for
developmental and biological research [2–5]. However,
the rapid growth of turtle aquaculture has led to
outbreaks of viral, bacterial, and parasitic diseases that
threaten the industry’s future development. Among these
outbreaks, soft-shelled turtle iridovirus (STIV) isolated
from T. sinensis with ‘red neck disease’ has caused great
economic losses [1], indicating an urgent need for effect-
ive diagnostic and therapeutic agents to control STIV
infections in aquaculture systems.
Aptamers are synthetic nucleic acids (single-stranded
DNA (ssDNA) or RNA) or protein ligands, selected using
systematic evolution of ligands by exponential
enrichment (SELEX) technology, which was first reported
in 1990 and since been widely used in many applications
[6, 7]. Aptamers have distinct three-dimensional struc-
tures and are characterized by complex structural features
including stems, loops, hairpins, and pseudoknots [8, 9].
Their high specificity, low immunogenicity and lack of
toxicity mean that aptamers have been used as specific
probes in many areas, such as diagnostics, pathogen de-
tection, and cancer research [10–14]. Current knowledge
of the viral life cycle has identified important markers
during its infectious process [15–19], relating to viral rep-
lication, assembly and release. These markers may serve
as target molecules for aptamer selection. RNA aptamers
with therapeutic potential for viral hemorrhagic septi-
cemia virus and Hirame rhabdovirus in fish have been
generated using purified virus particles as targets [20, 21].
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We previously selected a panel of DNA aptamers against
purified SGIV particles and demonstrated their inhibitory
effects on viral infection in vitro and in vivo [22].
The aim of the present study was to generate and
characterize a panel of ssDNA aptamers against intact
STIV using a SELEX iterative method. We investigated
the specificities of aptamer-binding to STIV and to
STIV-infected cells in vitro and to STIV-infected tissues
in vivo. The selected aptamers demonstrated good
potential as molecular probes for the development of
diagnostics and as drug-delivery vectors for controlling
STIV infection. We also evaluated aptamer-mediated
cytotoxicity and the effects of the aptamers on STIV
infection in cultured cells in vitro and in Chinese soft-
shelled turtles (Trionyx sinensis), in vivo.
Methods
Ethics statement
All experimental procedures on turtles were approved
by Ethical Committee of South China Sea Institute of
Oceanology, Chinese Academy of Sciences. Procedures
involving turtles were carried out in accordance with the
guidelines issued by the Ethical Committee of Chinese
Academy of Sciences, as described previously [22]. All
sections of this report adheres to the ARRIVE guidelines
for reporting animal research.
Viruses and cell lines
STIV (strain 9701) and Singapore grouper iridovirus
(SGIV, strain A3/12/98) were preserved in our labora-
tory [23, 24]. Fathead minnow (FHM) cells were grown
and maintained in Leibovitz’s L-15 medium supple-
mented with 10 % fetal bovine serum (Gibco, Life
Technologies, Carlsbad, CA, USA) at 28 °C, as described
previously [25, 26]. Virus titer was determined based on
the 50 % tissue culture infective dose (TCID50) [27].
Initial library and primers for SELEX
The SELEX library (Sigma-Aldrich, St. Louis, MO, USA)
comprised 44.7 nmol ssDNA, as described and used previ-
ously [22]. It included two primer-hybridization sequences
and a central randomized 50-nucleotide sequence (N50)
(5'-GACGCTTACTCAGGTGTGACTCG-N50-CGAAGG
ACGCAGAGAAGTCTC-3'). The 5′-primer (5′-GACGC
TTACTCAGGTGTGACTCG-3′) was labeled with
fluorescein isothiocyanate (FITC) or tetramethyl-6-
carboxyrhodamine (TAMRA), and the 3'-primer (5'-GA
GACTTCATCTGCGTCCTTCG-3′) was biotinylated.
Whole-virus SELEX
The ssDNA aptamers were selected based on the SELEX
protocol reported by Pan et al. (1995), with some modi-
fications [28]. For the first selection cycle, ssDNA
(10 nmol) was denatured at 94 °C for 10 min, cooled on
ice for 10 min, and then dissolved in 200 μl binding
buffer (100 mM NaCl, 2.5 mM MgCl2, 20 mM Tris–HCl
(pH 7.5)). A polyvinylidene difluoride (PVDF) filter
(0.1 μm)(EMD Millipore, Billerica, MA, USA) was pre-
wetted and the dissolved ssDNA was passed through the
filter to remove non-specific-bound ssDNA. The filtrate
was collected and incubated with 100 μl purified STIV
(109 TCID50/ml) for 1 h on ice. Another pre-wetted filter
was used to separate the unbound ssDNAs from the
ssDNA-STIV complexes. After washing with binding
buffer, the ssDNA-STIV complexes were collected from
the filter with TN buffer (150 mM NaCl, 50 mM Tris–
HCl (pH 7.5)), and heated at 95 °C for 5 min to dissoci-
ate the bound ssDNA. The dissociated aptamers were
amplified by polymerase chain reaction (PCR) (25 cycles
of denaturation at 94 °C for 1 min, annealment at 60 °C
for 30 s, and extension at 72 °C for 1 min, followed by a
final extension at 72 °C for 5 min). The sense ssDNA
was then isolated by heating the PCR products at
95 °C for 5 min followed by immediate cooling on
ice for 10 min. Pierce streptavidin magnetic beads
(100 μl) (Takara-Bio, Shiga, Japan) were added to
separate the biotin-conjugated antisense and sense
ssDNAs using a MiniMACS Separator (Miltenyi Biotec,
Cologne, Germany). Sense ssDNAs were collected and
used for further selection. We enhanced the specificity
and affinity of the selected aptamers by serially decreasing
the incubation time and STIV and ssDNA contents.
Selection and isolation of DNA aptamers
The final ssDNA pool was PCR-amplified using un-
labeled primers. The PCR products were then ligated
into the pMD18-T vector (Takara-Bio) and transformed
into Escherichia coli (DH5α), as described previously [29].
A total of 200 isolated clones were picked and sequenced.
DNA sequences present in more than two clones were
chosen as candidate aptamers and synthesized by Life
Technologies. The secondary structure of the aptamers
was predicted using MFOLD software (http://mfold.rna.
albany.edu/?q=mfold/DNA-Folding-Form), as described
previously [22].
Electrophoretic mobility shift assay
The specificity of aptamer-STIV binding was verified by
electrophoretic mobility shift assay (EMSA), as described
previously [20–22]. Each aptamer (7.5, 15 or 30 μg,
respectively) was incubated with 100 μl purified STIV
(109 TCID50/ml) for 1 h on ice. The ssDNA-STIV
complexes were then filtered through a 0.1-μm pre-
wetted PVDF filter (EMD Millipore) to remove unbound
aptamers. After elution from the filter with TN buffer,
the aptamer-STIV complexes were loaded onto a non-
denaturing gel (6 %) for polyacrylamide gel electrophor-
esis. The gel was stained with SYBR Green EMSA stain
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and visualized by UV epi-illumination at 312 nm, follow-
ing the manufacturer’s instructions (Life Technologies).
Aptamers incubated with SGIV (109 TCID50/ml) served
as controls to demonstrate aptamer-specific binding.
Fluorescent localization of STIV-aptamer binding
The specificity of aptamer-STIV binding was further
verified by fluorescent localization, as described previ-
ously [30], with some modifications. STIV was labeled
with the aptamers as follows: FITC-aptamers were dena-
tured at 95 °C for 5 min and cooled on ice for 10 min,
followed by the addition of 100 μl purified STIV (109
TCID50/ml) and incubation on ice for 1 h. The aptamer-
STIV mixtures were passed through a pre-wetted 0.1-μm
PVDF filter (EMD Millipore) and eluted from the filter by
washing with TN buffer. The chemical dye Hoechst
33,342 was then added to label the virus. After washing
three times, the samples (10 μl) were dropped onto a glass
coverslip and imaged using a fluorescence microscope
(Leica DMRXA, German) at an excitation wavelength
of 488 nm (green for FITC) or 350 nm (blue for
Hoechst 33,342). The FITC-library pool and SGIV
served as controls.
Measurement of STIV-biotinylated ssDNA aptamer
interaction by enzyme-linked immunosorbent assay
The aptamer-STIV binding interaction was measured
by enzyme-linked immunosorbent assay (ELISA), as
described previously [31], with some modifications.
5′-Biotinylated ssDNA aptamers were synthesized by
Life Technologies. The aptamers were heated at 95 °C
for 5 min and cooled on ice for 10 min. STIV (109
TCID50/ml) was incubated with each aptamer (200 nM)
in binding buffer and the mixtures were passed through a
pre-wetted 0.1-μm PVDF filter (EMD Millipore). After
washing with binding buffer, the 5′-biotinylated aptamer-
STIV complexes were eluted from the filter and trans-
ferred to 96-well plates (Pierce, USA). The bound
aptamers were detected using streptavidin-conjugated
horseradish peroxidase (HRP) (1:10,000, Pierce). After
adding 50 μl 2 M H2SO4 to terminate the color reac-
tion, the absorbance of each well was measured at
450 nm using an ELISA plate reader.
Analysis of binding affinity
The binding affinities of the aptamers were analyzed as
described previously [32]. 5′-Biotinylated aptamers at
various concentrations (0–500 nM) were incubated with
STIV (109 TCID50/ml) for 40 min on ice. The biotinyl-
ated ssDNA-STIV complexes were then filtered through
0.1-μm pre-wetted PVDF filters (EMD Millipore) to
remove unbound aptamers. After elution from the filter
with TN buffer, the aptamer-STIV complexes were trans-
ferred to 96-well plates (Pierce) and detected using
streptavidin-conjugated HRP (1:10,000, Pierce). The
samples were incubated with TMB chromogen solution
for 10 min. After adding 50 μl 2 M H2SO4 to terminate
the color reaction, the absorbance of each well was
measured at 450 nm using an ELISA plate reader. The
library incubating with STIV were served as the con-
trol.. After subtracting the mean values of the control
groups according to the equation: Y = BmaxX/(Kd + X),
the apparent equilibrium dissociation constants (Kd) of
the aptamer-STIV interactions were calculated using
SigmaPlot software [33]. Results for each aptamer was
presented as the mean ± SD of three independent
experiments.
Cytotoxicity assays
Cytotoxicity analyses of the selected aptamers were
based on the assays described by [34]. FHM cells in 96-
well plates were incubated with each aptamer candidate
at various concentrations (1–1000 nM) at 28 °C for 48 h,
with untreated FHM cells as a control. To assess cell
viability, 20 μl MTT solution (Takara-Bio) was added to
each well and incubated for 4 h at 28 °C. The color
change at 450 nm was measured using an ELISA plate
reader. The results of at least three assays were averaged
independently for each aptamer.
Effect of aptamers on STIV infection in cultured cells
The inhibitory effects of the selected aptamers on STIV
were assessed as described previously [22, 34]. Each se-
lected aptamer (500 nM) was incubated with STIV
(multiplicity of infection (MOI) = 0.5) and added simul-
taneously to FHM cells in a 24-well plate. SELEX library
(500 nM) incubated with STIV (MOI = 0.5) or STIV
alone (MOI = 0.5) were added to the cells as controls.
The cells were examined by light microscopy at 48 h post-
infection (p.i.), to detect the cytopathic effect (CPE). Mix-
tures of supernatant and cells in each well were collected
to determine virus titers by TCID50 assay [28]. Data from
three independent experiments were used to quantify the
effects of each selected aptamer on virus infection.
Protective effects of aptamers against STIV in vivo
Apparently healthy Chinese soft-shelled turtles (approxi-
mately 5 g) were obtained from a local aquaculture farm,
Guangdong, China. The turtles were maintained in tanks
with a closed re-circulating dechlorinated-water system
and fed daily with a commercial diet. Chinese soft-
shelled turtles were starved for 24 h prior to the experi-
ment. Five groups of turtles (n = 30 each) were treated
by intraperitoneal injection as follows: 60 μg selected
aptamer incubated with 100 μl STIV (108 TCID50/ml);
60 μg initial library incubated with 100 μl STIV (108
TCID50/ml); 60 μg selected aptamer only; 100 μl STIV
(108 TCID50/ml) only; untreated controls. Each group
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was transferred to a separate aquarium with ample
aeration and running water and mortality was recorded
daily up to 10 days p.i. Turtles in each group were
anaesthetized in ethyl 3-aminobenzoate methanesulfo-
nate solution (60 mg/L). Liver and spleen tissues were
harvested from each turtle, and washed with 10 ml
phosphate-buffered saline (PBS). After being fixed with
10 % neutral buffered formalin, each tissue was proc-
essed as paraffin and frozen section, respectively, as
described previously [22]. Liver and spleen tissues were
also ground in phosphate-buffered saline (PBS) and then
centrifuged, and the supernatant was collected and
filtered through a 0.22-μm filter (Millipore). The filtrates
were transferred to FHM cells at 28 °C and the CPE was
examined daily.
Flow cytometric analysis and fluorescent imaging
The specificity of aptamer candidate binding to STIV-
infected cells was evaluated by flow cytometric analysis
and fluorescence microscopy [34, 35]. The FITC-labeled
aptamers were first denatured at 94 °C for 10 min and
cooled on ice for 10 min. After washing three times with
PBS (2 mmol/l KH2PO4, 10 mmol/l Na2HPO4 · 12H2O,
137 mmol/l NaCl, 1‰NaN3), STIV-infected FHM cells
were incubated with FITC-labeled aptamers in 200 μl
binding buffer on ice for 40 min, washed twice with
Fig. 1 SELEX isolated eight aptamers that specifically targeted STIV particles. a Binding to STIV was enhanced in the higher selected pools, as
demonstrated by ELISA. b Cluster analysis of the selected aptamers. c Secondary structures of aptamers QA-36, QA-92, QA-9, and QA-12. The
stabilities of aptamer secondary structures were calculated as the free energy (ΔG)
Table 1 Identification of ssDNA aptamers
Aptamer Central randomized sequences Frequency
QA-92 CGGGTGCCTTAAAGTGTAGGTGGGAGGGGGATGATTATGTACGATCAAGT 26 %
QA-9 GAAGGTGGAGCGGTTAGGATACTAGCGAATGAAGACACGTTAGCTGATCT 23 %
QA-12 AGTGGGTAAGGTCTGGTGGATTGTGGACGGGGGGCGGGGCAGTGGCTTGA 21 %
QA-36 TGTGCGGGGGAGGGGAGTGGCGCTGTTGGTGCGGGTATAGCGCGTGGTGT 18 %
QA-17 AGAGGGTCGGTCGTAGTGGATTTGGCGCATTGTTCTGCGGGGTGGGAGGG 2 %
QA-79 GTCGGGACAGTGTTGGTCCTCAGGATCTCTGGGGCGCGGGGTTAAACAGT 2 %
QA-41 TGTTCGGGTTATTGCTCCTCCTTATTGTCACCTGGATGTATGATCGTGTAG 4 %
QA-88 GGATAGGGGGCTCGCTCGTTCCGTAGCGATGCAGGTTTCTTATTCACGAA 2 %
Consensus -GG———————G———T-
Frequency indicates the percentage of the 8th selected pool comprised by each aptamer. Consensus regions within the representative aptamers are bold
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PBS, and then resuspended in 400 μl PBS. FITC fluor-
escence was measured using a FACScan cytometer
(BD Immunocytometry Systems, USA) by counting
20,000 events. The FITC-labeled initial library incu-
bated with STIV-infected FHM cells were used as the
control.
After denaturing at 94 °C for 10 min and cooling on
ice for 10 min, FITC-labeled aptamers (300 nM) were
incubated with 105 STIV-infected FHM cells per well in
24-well plates at 4 °C for 1 h in the dark. The cells were
then fixed with 4 % paraformaldehyde and washed three
times with PBS. Fluorescent imaging of the cells was
Fig. 2 Analysis of binding specificity of anti-STIV ssDNA aptamers. a EMSA of selected aptamers incubated with STIV (lane 1, 7.5 μg aptamer only;
lanes 2–4, STIV incubated with 7.5, 15 or 30 μg of each aptamer, respectively; lane 5, 30 μg of aptamer only; and lane 6, STIV only). b EMSA of selected
aptamers incubated with SGIV. Note that no bands were visible in lanes 5–9, which proved the specificity of selected aptamers only recognizing STIV.
c, d Fluorescent localization of STIV-aptamer binding in virus particles stained with Hoechst 33,342. c Imaging of FITC-aptamer-labeled STIV virus
particles by fluorescence microscopy. d Controls of FITC-aptamers not binding to SGIV, and initial library not binding to STIV. (Bars = 50 μm)
Fig. 3 Affinity of STIV-selected ssDNA aptamer interactions by ELISA. STIV was incubated with increasing concentrations of 5′-biotinylated aptamer.
After addition of streptavidin-HRP, the amount of STIV-aptamer complex was calculated and graphed as a function of aptamer concentration. The
graph was fit to the equation Y = Bmax*X/(Kd + X) using SigmaPlot software. Results for each aptamer was presented as the mean ± SD of three
independent experiments
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performed using a fluorescence microscope (Leica
DMRXA, German) at an excitation wavelength of
488 nm (green for FITC) or visible light. The initial
library incubated with STIV-infected FHM cells and
aptamers incubated with normal FHM cells were
used as the negative controls.
The protocols for TAMRA-labeled aptamers (300 nM)
binding to STIV-infected tissues were similar to fluores-
cent imaging of the cells, at 560 nm excitation (red for
TAMRA) and visible light. FITC-labeled initial library
and normal tissues were used as controls.
Statistical analysis
The experimental data are expressed as the mean ±
standard deviation (SD). Differences between groups
were compared by one-way analysis of variance. Values
of P < 0.05 were considered to represent statistically
significant differences. Statistical analysis was performed
using SPSS, version 13.0 (IBM, Armonk, NY, USA).
Results
Selection of ssDNA aptamers against STIV
Specific enrichment of each selected pool was monitored
by ELISA. ssDNA binding increased as the selection
cycles progressed, confirming that the selected pools
were specific to STIV. ssDNA binding to STIV peaked
at the 8th pool (Figure 1a), and eight ssDNA aptamers
were isolated from the 8th pool (Table 1) based on
their highly-specific STIV binding. We did an align-
ment of the selected aptamers, the consensus regions
within the individual aptamers were also shown in
Table 1, all aptamers held the specific motifs of
“-GG———————————————————————
G————————T-”. The QA-92 aptamer comprised
Fig. 4 Aptamers exhibited no cytotoxic effects in vitro and in vivo. a DNA aptamers exhibited no cytotoxicity in cultured cells. The results for each
group are presented as the mean ± SD of three independent experiments. b No pathological changes were found in liver and spleen tissues of
aptamer-injected turtles, compared with normal control turtles. The scale bars indicate 20 μm
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26 % of the aptamer pool, while the other aptamers
were less prevalent in the pool. Cluster analysis
showed that QA-92 was a single clade that did not
cluster with the other seven aptamers (Fig. 1b). QA-
92, QA-9, QA-12 and QA-36 comprised 88 % of the
aptamer pool and were selected for further analysis.
Secondary structures and free energy (ΔG) values of
the selected aptamers were calculated using the
MFOLD program. The aptamers all formed representa-
tive stem-loop structures, and QA36 had the lowest ΔG
value of −24.7 (Fig. 1c).
Selected aptamers bound STIV with high specificity
Specific aptamer-STIV binding was demonstrated by
EMSA assays. Free ssDNA aptamers appeared at the
bottom of the gel (Fig. 2a, lanes 1 and 5). Only single
bands were visible in the upper region of the gel in
the case of aptamers incubated with STIV (Fig. 2a,
lanes 2–4), indicating that the selected aptamers
bound STIV. When the aptamers were incubated with
a different virus (SGIV), no bands were observed in
the gel, which proved the specificity of aptamers only
recognizing STIV (Fig. 2b).
The specific binding of aptamers to STIV was also
demonstrated by fluorescent imaging of FITC-
aptamer-labeled STIV virus particles by fluorescence
microscopy. STIV virus particles labeled with FITC-
aptamers and Hoechst 33,342 were evident and colo-
calized (Fig. 2c). STIV virus particles incubated with
FITC-library and SGIV virus particles incubated with
FITC-aptamers as controls showed no colocalization
(Fig. 2d).
Binding affinities of selected ssDNA aptamers with STIV
The binding affinities of the aptamers to STIV were
assessed by ELISA using 5′-biotinylated aptamers. All
the four selected aptamers showed high affinity for STIV,
with calculated binding affinities (Kd) of 77.5 nM for
QA9, 80.7 nM for QA12, 53.8 nM for QA36, and 71.2
nM for QA92 (Fig. 3). Of the four aptamer candidates,
the Kd value of QA36 indicated the highest affinity.
Cytotoxic effects of aptamers in vitro and in vivo
We incubated cells with the selected aptamers and then
evaluated cell viability by the MTT method. There were
no significant differences between the control and ex-
perimental groups, even at aptamer concentrations up to
1000 nM, suggesting that the aptamers were not cyto-
toxic (Fig. 4a). Furthermore, no turtles in the aptamer-
treated or control groups had died 10 days p.i.. There
were no pathological changes were in the liver or spleen
in aptamer-injected turtles compared with controls, indi-
cating that the selected aptamers had no cytotoxic ef-
fects in vivo (Fig. 4b).
Inhibition of STIV infection by aptamers in vitro and
in vivo
Cells without any treatment were served as mock group
and grew normally. Cells incubated with SELEX library
or aptamers also maintained normal growth, it indicated
that selected aptamers exhibited no cytotoxic effects in
cell cultures, which was consistent with the results of
Fig. 4. (Fig. 5a). The inhibitory effects of aptamers was
shown in Fig. 5b. There were significant CPEs in control
cells incubated with STIV alone, when our aptamers
were added, although there were some CPEs, the CPEs
were much less than the control groups, which means
STIV infection could be partially inhibited by the
selected aptamers (Fig. 5b). Virus titers were significantly
reduced by all the aptamers at 48 h post-infection, with
Fig. 5 Selected aptamers inhibited STIV infection in cultured cells. a
Morphology of FHM cells following treatment with the SELEX library
or selected aptamers. b Cell morphology and CPE after treatment with
STIV previously incubated with or without selected aptamers. c Aptamers
reduced virus titers in cultured cells. d QA-36 aptamer inhibited STIV
infection in a dose-dependent manner. The results for each group are
presented as the mean ± SD of three independent experiments.
(**P < 0.01; *P < 0.05; bars = 50 μm)
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QA-36 displaying the greatest inhibitory effect on STIV
among the tested aptamers (Fig. 5c).
QA-36 was incubated with STIV at concentrations of
100, 250, 500, or 1000 nM and then added to the cells.
The virus titers at 48 h p.i. showed that QA-36 inhibited
STIV infection in a dose-dependent manner (Fig. 5d).
Inhibition of STIV infection in vivo by QA-36
QA-36 had the highest affinity for (Fig. 3) and demon-
strated the most effective inhibition of STIV (Fig. 5d),
and its inhibitory effects against STIV in soft-shelled
turtles were therefore studied further. Turtles injected
with STIV alone showed 10 % mortality on day 3,
increasing to 100 % on day 8 p.i.. In contrast, no
turtles injected with the mixtures of QA-36 and STIV
died until day 5 p.i. and the cumulative mortality was
80 % (Fig. 6a), suggesting that QA-36 inhibited STIV
infection in vivo.
Red congestion, bleeding, and ulceration as typical
characteristics of STIV infection were evident in the
neck, shell and mouth of the dead turtles, and dissection
revealed red congestion and bleeding in the liver and
spleen. Filtrates from the ground liver and spleen of
dead turtles after 24 h p.i. demonstrated a CPE when
incubated with FHM cells at 28 °C, and this effect was
more significant after 48 h p.i. (Fig. 6b).
STIV aptamer QA-12 specifically recognized STIV-infected
cells and tissues
To determine if aptamers against STIV recognized STIV-
infected cells, we incubated FITC-aptamers (300 nM) with
STIV-infected FHM cells and monitored the process by
flow cytometry. The FITC-labeled initial library incubated
with STIV-infected FHM cells were used as the control.
Compared to the control, the fluorescence intensity of
QA-12 increased in STIV-infected FHM cells, though the
effects of QA-9, QA-36 and QA-92 were less noticeable,
which means only QA-12 bound to STIV-infected cells,
while QA-9, QA-36, QA-92 and the library could not bind
to STIV-infected cells (Fig. 7a). These results were verified
by imaging infected cell-aptamer interactions (Fig. 7b).
Aptamer QA-12 evolved against STIV could thus
recognize STIV-infected FHM cells. Fluorescent images of
liver and spleen tissues indicated that the selected
aptamers bound STIV-infected liver and spleen tissues
with high levels of specificity (Fig. 7c).
Fig. 6 QA-36 inhibited STIV infection in cultured turtles. a Cumulative mortality of turtles was recorded daily up to 10 days p.i.. QA-36 slowed the
rate of STIV infection and reduced the cumulative mortality by 20 %. b Filtrates collected from ground liver and spleen tissues of dead turtles
exerted a CPE in FHM cells. (Bars = 100 μm)
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Discussion
STIV is an important causative agent isolated from soft-
shelled turtles (T. sinensis) with ‘red neck disease’ [1].
However, no commercial vaccine against STIV is currently
available, and effective strategies for detecting and inhibit-
ing STIV infection are thus urgently needed. Highly sensi-
tive and specific aptamers have been shown to have many
applications [36]. They have been developed as promising
candidates for antiviral therapeutics, and have demon-
strated impressive results in animal-based studies and
clinical trials [8, 9, 11, 36].
In the present study, we generated four ssDNA aptamers
targeting STIV. Compared with the purified-protein-based
SELEX method, aptamers selected through whole-virus-
based SELEX could bind unknown targets on the virus sur-
face, and may thus serve as effective biomarkers for study-
ing the STIV infectious mechanism. In addition, viral
surface proteins retain their native conformations, which
are critical for biological functions [28]. FITC-aptamers
could successfully recognize and label STIV virus particles,
indicating their potential as commercially available probes
for the early and rapid diagnosis of viral infection. More-
over, aptamers may also provide an alternative method for
the real-time imaging of virus infection pathways. To the
best of our knowledge, this study provides the first report
of the ability of aptamers to inhibit and recognize STIV
infection.
Aptamers have complex three dimensional structures
including hairpins, stem-loops, and bulges, and are
maintained by hydrogen bonding, electrostatic interac-
tions and hydrophobic forces, which form the basis for
tight aptamer binding to their targets [6]. Through
competing for targets, aptamers may affect other inter-
actions, such as virus-cell attachment. Hwang et al.
(2012) reported antiviral aptamers that may bind to
virus glycoproteins responsible for mediating virus
entry into the cell [20]. The aptamers selected in the
current study formed representative stem-loops in their
Fig. 7 Some selected aptamers bound STIV-infected FHM cells with a high level of specificity. a Fluorescence intensities of four selected
FITC-aptamers binding to infected FHM cells. The fluorescence intensity of QA-12 was increased in STIV-infected FHM cells compared with
QA-9, QA-36 and QA-92. The FITC-labeled initial library incubated with STIV-infected FHM cells were used as the control (black). b Fluorescent images
of four FITC-aptamers with STIV-infected FHM cells. QA-12 bound to STIV-infected cells but not to normal cells. QA-9, QA-36, QA-92 and the library
bound to neither STIV-infected cells nor normal cells. The initial library incubated with infected cells and aptamers incubated with noamal cells were
used as the negative controls. c Fluorescent images of four FITC-aptamers with STIV-infected turtle tissues. QA-12 bound to STIV-infected liver and
spleen tissues but not to normal tissues. QA-9, QA-36 and QA-92 bound to neither STIV-infected tissues nor normal tissues. The initial library was used
as a negative control. Left: bright field; right: fluorescent. (Bars = 20 μm)
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complex secondary structures. QA-36 had the lowest
ΔG value, indicating that its secondary structure was
the most stable. Regarding the inhibitory capacity of
aptamers, we speculated that their stem-loops might
form target-binding sites allowing them to bind to
their targets and interfere with STIV infection.
Flow cytometry and fluorescent imaging confirmed that
the aptamer QA-12 was able to recognize STIV-infected
cells. We speculate that STIV changes and rebuilds cell
structures through the process of infection, causing some
viral proteins or cell surface antigens to appear on the
membranes of infected cells, which subsequently become
part of the STIV envelope during its release. Aptamers
bound to targets on both the infected-cell membrane, and
the STIV envelope during the selection process. Aptamers
are thus suitable molecular probes for the development of
highly-specific diagnostics for detecting STIV infections.
The key to developing therapeutic reagents for in vivo
application lies in their high specificity, low immunogen-
icity and lack of toxicity, thus reducing the side-effects
associated with non-specific drug targeting. As highly-
specific probes, aptamers are promising candidates for
the targeted delivery of therapeutic reagents to the
pathogen [37–39]. In this study, we confirmed that the
selected aptamers had no cytotoxic effects either in vitro
or in vivo, consistent with previous reports [22, 34]. Fur-
thermore, QA-12 could recognize STIV-infected cells,
and the use of aptamers in delivery vehicles provides a
means of conferring selectivity to cell-type-specific inter-
actions. This could also result in cellular internalization
of the aptamers by the target cells, thereby increasing
the therapeutic efficacy and reducing potential toxicities
of the delivered drug. The molecular characteristics of
cells infected by viruses, especially at the proteomic
level, are critical for our understanding viral patho-
genesis and for designing targeted therapies [16–19].
Further studies are therefore warranted to identify the
viral mechanisms disrupted by binding of the aptamer
QA-12.
Conclusions
We generated DNA aptamers that bound STIV with a
high level of specificity, providing an alternative
means for identifying STIV and for real-time imaging
of the virus-infection pathways. The selected aptamers
inhibited STIV infection in vitro and in vivo, withQA-
36 representing a particularly promising candidate
therapeutic agents for blocking STIV infection. QA-12
also recognized STIV-infected cells and tissues, and
could therefore be developed as candidate agents for
investigating STIV pathogenesis, drug development,
and medical therapies for STIV infection. This study
provides the first evidence for aptamers with the
capacity to inhibit and recognize STIV infection.
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